FDA approvals, CRLs, advisory committees, clinical holds and guidance — every shift in the U.S. regulatory posture.
The FDA has approved Eli Lilly's BTK inhibitor Jaypirca for first-line treatment of chronic lymphocytic leukemia (CLL). The current feed provides only the headline and no further details on trials, dosing, or the basis for approval.
Why it matters: Heat: 4 sources reported the same event
The FDA has extended its review of Novo Nordisk's marketing application for Denecimig, a FIX/FX bispecific antibody, delaying a regulatory decision that had been expected in the third quarter of this year. Novo Nordisk filed the application in September after Denecimig received breakthrough therapy designation, and it still plans a commercial launch in the first half of next year. Roche's next-generation FIX/FX bispecific NXT007 has advanced to phase three trials.
Why it matters: Delayed FDA review of a breakthrough-designated haemophilia candidate shifts Novo Nordisk's launch timing.
FDA approved Eli Lilly's pirtobrutinib (Jaypirca) on October 2, 2026 for adults with previously untreated CLL or SLL without 17p deletion. In the BRUIN CLL-313 trial of 282 patients randomized to pirtobrutinib or bendamustine plus rituximab, median PFS was not estimable with pirtobrutinib versus 33.5 months in the control arm (hazard ratio 0.20, p<0.0001) at a median follow-up of 28 months. The recommended dose is 200 mg orally once daily until progression or unacceptable toxicity.
Why it matters: FDA approval of pirtobrutinib moves the BTK inhibitor into first-line CLL/SLL treatment based on a 0.20 hazard ratio.
The FDA has released a Transparency Roadmap covering FY26 milestones and FY27 priorities, aiming to maximize disclosure of its regulatory reasoning. A centerpiece is its complete response letter disclosure initiative, launched in 2025 with more than 200 letters covering applications submitted between 2020 and 2024, after a 2015 internal analysis found 85 percent of the FDA's safety and efficacy concerns went unmentioned in sponsors' public announcements of non-approvals. The agency also plans rulemaking to disclose the fact of submission of NDAs, BLAs and ANDAs, and is encouraging sponsors to make IND filings public, as about 96 percent of novel drug or biologic filings are already disclosed.
Why it matters: FDA transparency roadmap details new CRL and application disclosure policies that affect how sponsors communicate regulatory setbacks.
VYD2311, a monoclonal antibody against the novel coronavirus on the same backbone as the authorized Pemgarda and the investigational adintrevimab, met the primary safety endpoint in the phase 3 LIBERTY trial of 210 healthy adults aged 18 to 49 across three arms: VYD2311 alone, with an mRNA vaccine, or vaccine alone. Tolerability was better than the mRNA vaccine and VYD2311 did not interfere with vaccine neutralizing titers. The company plans to submit a BLA to the FDA under the accelerated approval pathway as a pre-exposure prophylaxis, with key efficacy data from DECLARATION expected in October 2026.
Why it matters: Positive phase 3 safety topline for a pre-exposure prophylaxis monoclonal antibody moving toward an accelerated-approval BLA filing.
The FDA has approved Fayuvi (rebisufligene etisparvovec), a gene therapy developed by Ultragenyx Pharmaceutical, making it the first FDA-approved therapy for children with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. The rare inherited disease progressively damages the brain and nervous system, causing children to gradually lose cognitive, speech and other developmental abilities over time.
Why it matters: First-ever FDA approval of a therapy for children with Sanfilippo syndrome type A.
The FDA has approved iberdomide for multiple myeloma on the basis of minimal residual disease negativity, the first approval for the disease to use that endpoint. Iberdomide also represents a new generation of targeted protein degraders, with several more potent cereblon E3 ligase modulators already in clinical development.
Why it matters: First myeloma approval based on MRD negativity and a new class of cereblon E3 ligase modulators advancing.
The FDA approved the Autus Size-Adjustable Valve, developed by Autus Valve Technologies and approved via Edwards Lifesciences, for pediatric patients with congenital pulmonary valve disease. It is the first heart valve that can be expanded after implantation, growing from about 13 millimeters to up to 22 millimeters, and the first U.S.-approved valve with polymeric rather than animal-derived leaflets. Approval rests on a study of 62 pediatric patients at 12 U.S. sites, with no deaths or clot-related complications; longer-term studies are under way.
Why it matters: First FDA-approved expandable pediatric heart valve may cut repeat open-heart surgeries in children.
The Trump administration and HHS launched new programs to speed U.S. clinical trials as China and Australia attract more pharmaceutical research. The five-year Surpass program will fund teams with ideas such as a phaseless design engine and real-time analysis, while ARPA-H is starting three projects to speed enrollment and build nationwide data infrastructure. HHS says drug development now takes about 10 years and costs $1 billion to $2 billion, and Surpass manager Daria Fedyukina says innovations could halve timelines and cut costs tenfold.
Why it matters: US government moves to restructure clinical trials amid China and Australia gaining trial share.
Kyverna has started a rolling BLA submission to the FDA for miv-cel and plans to complete it in the fourth quarter of this year. If approved, miv-cel would become the first CAR-T therapy authorized for an autoimmune disease, moving CAR-T beyond oncology for the first time since its commercialization more than a decade ago.
Why it matters: Potential first FDA-approved CAR-T for autoimmune disease, a first move beyond oncology.
FDA placed Chengdu Shengnuo Pharmaceutical, a wholly owned subsidiary of the Shanghai STAR-listed peptide maker Shengnuo Biology, on Import Alert 66-40 on September 19, without first issuing a warning letter, meaning its products can be detained at US customs without inspection. The company disclosed the move on September 22. The action comes as US federal enforcers penalize a large Houston compounding pharmacy for GLP-1 weight-loss drugs and attorneys general from 20 states jointly press for tighter controls on GLP-1 compounders.
Why it matters: FDA import alert on a major Chinese peptide maker tightens the GLP-1 supply chain on both sides.
The FDA has approved AbbVie's JUVO (tavapadon) for adults with Parkinson's disease, announced on September 28, 2026. JUVO is the first and only approved selective D1/D5 receptor agonist and is taken once daily. The approval marks the first new-mechanism dopaminergic therapy for Parkinson's disease in decades.
Why it matters: First selective D1/D5 receptor agonist approval gives Parkinson's disease a new dopaminergic mechanism.
The FDA has expanded Bristol Myers Squibb's Camzyos (mavacamten) indication to cover symptomatic obstructive hypertrophic cardiomyopathy in adults and paediatric patients weighing at least 30kg. The decision rests on the Phase III SCOUT-HCM trial in 44 adolescents aged 12 to under 18, where the cardiac myosin inhibitor significantly reduced Valsalva LVOT gradient at week 28 versus placebo with no new safety concerns. Camzyos, first approved in 2022 and now cleared in more than 60 countries, is in discussions with other regulators for paediatric approvals.
Why it matters: FDA label expansion extends a cardiac myosin inhibitor into paediatric oHCM, a setting with significant unmet need.
The FDA has approved a new drug for pancreatic cancer that reportedly extends survival in patients. The approval was reported by Scientific American on August 26 and relayed by Chinese industry media on August 29. No drug name, trial details or dosing information were given in the report.
Why it matters: FDA approval of a new pancreatic cancer drug is relevant to clinicians despite sparse detail.
Edwards' EVOQUE transcatheter tricuspid valve replacement system, the first such system to hold both CE marking and FDA approval, has received special access in China and completed its first clinical uses at Beijing's Fuwai Hospital. The system offers an interventional option for patients with severe tricuspid regurgitation, including elderly patients with multiple comorbidities or high surgical risk. Broader use in Chinese patients is expected to follow.
Why it matters: First-in-class transcatheter tricuspid replacement reaches Chinese patients via special access pathway.
The FDA approved AbbVie's JUVMO (tavapadon) on September 25, 2026 for the treatment of Parkinson's disease in adults. JUVMO is the first and currently only selective D1/D5 receptor agonist approved for adult Parkinson's disease, and the article describes it as the first breakthrough in dopaminergic therapy for Parkinson's in decades.
Why it matters: First approval of a selective D1/D5 receptor agonist for Parkinson's disease in decades.
FDA issued a warning letter, reference 320-26-129, to Fresenius Kabi USA CEO Pierluigi Antonelli on September 22, 2026, citing CGMP violations found at its sterile injectable manufacturing facility in Melrose Park, Illinois, inspected from January 27 to February 18, 2026. FDA says the firm failed to adequately investigate drug product failures, including bioburden action limit failures linked to adverse events with famotidine for injection, leading to a recall of three famotidine injection batches after an endotoxin failure in retained samples. FDA found the company's March 11, 2026 response inadequate and warned that failure to correct violations may result in seizure or injunction.
Why it matters: FDA warning letter over CGMP failures at a major sterile injectables plant, with a famotidine recall tied to adverse events.
The FDA approved Camzyos (mavacamten) as the first treatment to improve functional capacity and symptoms in children with symptomatic obstructive hypertrophic cardiomyopathy, extending approval to pediatric patients weighing at least 30 kg, after adult approval in 2022. Efficacy was supported by the phase 3 SCOUT-HCM trial in 44 patients aged 12-18, where once-daily dosing for 28 weeks significantly reduced the Valsalva LVOT gradient versus placebo. The drug carries a boxed warning for heart failure risk and is available only through the Camzyos REMS program.
Why it matters: First pediatric approval for symptomatic oHCM, backed by phase 3 data in adolescents.
FDA is implementing the Adverse Event Monitoring System (AEMS), formerly FAERS, to consolidate reporting across all FDA-regulated product categories, with AI-based redaction, enhanced analytics and cross-product surveillance. From October 1, 2026, postmarketing individual case safety reports for human drugs, biologics and drug- or biologic-led combination products submitted via ESG NextGen must use E2B(R3) data standards, a six-month extension of the prior timeline; E2B(R2) remains accepted through September 30, 2026. Electronic submission of premarketing IND safety reports in E2B(R3) format became mandatory on April 1, 2026 for commercial IND sponsors using database-to-database transmission.
Why it matters: Sets firm 2026 deadlines and data standards for electronic adverse event reporting that affect every drug and biologics company's pharmacovigilance operations.
The FDA has accepted Roche's approval application for fenebrutinib, an experimental multiple sclerosis pill, under a priority review with a six-month timeline, covering both relapsed and primary progressive forms of the disease. The application rests on three late-stage studies that met their main objectives, but approval chances could be complicated by an imbalance in deaths, eight among fenebrutinib recipients versus one on Aubagio in two Phase 3 trials, and a case of liver enzyme elevations meeting Hy's law. Roche did not say when a decision might come.
Why it matters: Fenebrutinib could become the first BTK inhibitor approved for two major forms of MS despite unresolved safety concerns.
